XML 13 R2.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Condensed Consolidated Balance Sheets (Unaudited) - USD ($)
$ in Thousands
Mar. 31, 2024
Dec. 31, 2023
Current assets:    
Cash and cash equivalents $ 105,734 $ 113,688
Short-term investments 71,865 121,898
Accounts receivable, net ($7,122 and $6,079 from related parties) 37,083 12,553
Inventories 27,335 41,565
Prepaid expenses and other current assets 36,150 41,855
Total current assets 278,167 331,559
Restricted time deposits 1,658 1,658
Property and equipment, net 12,166 13,126
Equity method investment in unconsolidated variable interest entity 5,776 5,290
Operating lease right-of-use assets 64,751 68,093
Other assets 3,350 3,803
Total assets 365,868 423,529
Current liabilities:    
Accounts payable 4,353 17,960
Accrued and other current liabilities ($45,870 and $39,814 to a related party) 164,286 172,891
Deferred revenue ($7,901 and $7,220 to related parties) 12,863 12,740
Operating lease liabilities, current 15,231 14,077
Total current liabilities 196,733 217,668
Product development obligations 17,446 17,763
Deferred revenue, net of current ($2,343 and $9,705 to a related party) 147,118 157,555
Operating lease liabilities, non-current 62,511 66,537
Senior secured term loan facilities, non-current 72,213 71,934
Liability related to sale of future revenues, non-current 52,216 51,413
Other long-term liabilities ($2,458 and $656 to a related party) 3,786 2,858
Total liabilities 552,023 585,728
Commitments and Contingencies (Note 12)
Redeemable non-controlling interests 21,480 21,480
Stockholders' deficit:    
Preferred stock, $0.01 par value; 125,000 shares authorized; no shares issued and outstanding at March 31, 2024 and December 31, 2023
Common stock, $0.01 par value; 225,000 shares authorized at March 31, 2024 and December 31, 2023; 99,474 and 98,770 shares issued and outstanding at March 31, 2024 and December 31, 2023 995 988
Additional paid-in capital 1,652,243 1,643,641
Accumulated other comprehensive loss (6,507) (6,875)
Accumulated deficit (1,874,853) (1,841,920)
Total stockholders' deficit attributable to FibroGen (228,122) (204,166)
Nonredeemable non-controlling interests 20,487 20,487
Total deficit (207,635) (183,679)
Total liabilities, redeemable non-controlling interests and deficit $ 365,868 $ 423,529